Embracing Project Optimus: Can we Leverage Evolutionary Theory to Optimize Dosing in Oncology?

oncology, precision medicine, tumor evolution, dosing, FDA

Focus on tumor evolution, which leads to therapeutic failure and disease relapse. Emphasis on the effect of tumor evolution on the exposure-response (E-R) relationships of oncology drugs. Advocacy for prioritizing tumor evolution during clinical development to select optimal doses for targeted t…

Sep 2^nd • 10 mins read

Transforming oncology: Five frontiers driving progress in cancer care

Thought Leadership, Oncology

From biomarker-driven breakthroughs to AI-powered early detection and a renewed commitment to equity and patient centricity, the past 12 months have seen major strides across cancer research, treatment, and communication. At Inizio, we’ve had a front-row seat to this transformation, supporting…

May 16^th • 5 mins read

Rise of Antibody-Drug Conjugates: The Present and Future

Antibody, Drug Conjugates

Antibody-drug conjugates (ADCs) are designed for targeted cancer therapy by delivering cytotoxic agents specifically to tumor cells, minimizing harm to normal cells. ADCs have evolved significantly since the first FDA approval in 2000, with advancements leading to approvals for various tumor type…

May 25^th • 20 mins read